Crinetics Pharmaceuticals (CRNX) AI Stock Analysis

• Market Cap: $3.19B
• Dividend Yield: N/A
• Average Volume (3M): 908.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: N/A
• EPS Growth: -0.12%
• Country: US
• Employees: 290
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -3.70
• Shares Outstanding: 93,048,540
• 10 Day Avg. Volume: 1,067,626
• 30 Day Avg. Volume: 908,989
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 3068.18
• Price to Cash Flow (P/CF): -12.30
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $79.00
• Price Target Upside: 130.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

Crinetics Pharmaceuticals is currently facing financial challenges with persistent losses and cash flow issues, impacting its overall stock score negatively. Despite significant advancements in drug approvals and clinical trials, which provide optimism for future growth, the current bearish technical indicators and lack of profitability or dividends weigh heavily on the stock's attractiveness. The company's strategic focus and progress in regulatory milestones are encouraging but need to be balanced against its financial instability.

Positive Factors

Financial Position

Crinetics Pharmaceuticals ended the quarter with $1.4 billion in cash, cash equivalents, and investments, which should fund operations for an extended period.

Regulatory Progress

The FDA accepted Crinetics’ NDA for paltusotine for acromegaly with no Advisory Committee meeting anticipated, which is viewed as a positive signal for approval given the convincing clinical data.

Negative Factors

Safety Concerns

CRNX shares have been trading down following safety concerns from the Phase 2 atumelnant data in congenital adrenal hyperplasia (CAH) reported in January 2025.

Crinetics Pharmaceuticals Business Overview & Revenue Model

Company Description

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

How the Company Makes Money

Crinetics Pharmaceuticals primarily makes money through the development and eventual commercialization of its drug candidates. The company's revenue model is centered on bringing its investigational therapies to market, which involves various stages of clinical trials and regulatory approvals. Key revenue streams are anticipated from product sales upon successful commercialization of its drug candidates. Additionally, Crinetics may enter into strategic partnerships or licensing agreements with other pharmaceutical companies to co-develop or market its products, which could provide milestone payments, royalties, and other financial incentives. However, as a clinical-stage company, the majority of its current funding is likely sourced from investments, grants, and public offerings to support its research and development efforts.

Crinetics Pharmaceuticals Financial Statement Overview

Summary

Crinetics Pharmaceuticals faces significant financial challenges, with persistent operational losses and cash flow issues. While recent financing has strengthened the cash position, the company's ability to generate sustainable revenue and profit remains unproven. The balance sheet shows improvement, but historical financial instability highlights the need for caution.

Income Statement

Crinetics Pharmaceuticals has experienced fluctuating revenue with a decline from 2022 to 2023, followed by a sharp drop in 2024. The gross profit margin is consistently high, but net losses persist, indicating ongoing profitability challenges. Negative EBIT and EBITDA margins reflect operational inefficiencies.

Balance Sheet

The company shows a strong equity position with substantial cash reserves and minimal debt. However, negative stockholders' equity in earlier years indicates past financial distress. Current liabilities are relatively low, but the debt-to-equity ratio is a concern due to historical negative equity.

Cash Flow

Operating cash flow remains negative, highlighting potential liquidity challenges. Free cash flow is also consistently negative, though recent financing activities have bolstered cash reserves. Stability in cash flow remains a concern with ongoing operational losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.04M	4.01M	4.74M	1.08M	71.00K
	Gross Profit
1.04M	4.01M	3.35M	-184.00K	-56.93M
	EBIT
-338.85M	-222.61M	-167.88M	-107.70M	-74.95M
	EBITDA
-338.85M	-221.51M	-166.90M	-106.78M	-72.59M
	Net Income Common Stockholders
-298.41M	-214.53M	-159.95M	-106.72M	-72.86M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.35B	558.55M	334.43M	333.71M	170.88M
	Total Assets
1.43B	635.35M	352.18M	351.01M	183.44M
	Total Debt
51.72M	51.73M	2.02M	3.07M	4.01M
	Net Debt
-212.82M	-3.17M	-30.65M	-197.62M	-89.07M
	Total Liabilities
109.79M	96.25M	35.85M	19.07M	14.53M
	Stockholders Equity
1.32B	539.11M	-439.17M	-275.25M	-167.61M
Cash Flow		Free Cash Flow
-229.81M	-171.00M	-116.86M	-89.02M	-62.21M
	Operating Cash Flow
-225.97M	-166.31M	-115.20M	-88.59M	-62.03M
	Investing Cash Flow
-574.82M	-200.41M	-173.98M	-56.48M	217.00K
	Financing Cash Flow
1.01B	388.94M	121.96M	252.68M	114.57M

Crinetics Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 34.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRNX, the sentiment is Neutral. The current price of 34.26 is below the 20-day moving average (MA) of 34.68, below the 50-day MA of 38.87, and below the 200-day MA of 49.05, indicating a neutral trend. The MACD of -1.38 indicates Negative momentum. The RSI at 47.45 is Neutral, neither overbought nor oversold. The STOCH value of 50.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRNX.

Crinetics Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGND	72 Outperform	$2.04B	48.01	-0.53%	―	27.28%	-101.63%
NBIX	68 Neutral	$10.69B	33.14	14.16%	―	24.81%	33.67%
RARE	54 Neutral	$3.55B	―	-214.50%	―	29.01%	23.93%
Sector *	49 Neutral	$6.90B	0.02	-54.05%	2.46%	24.91%	-3.14%
CRNX	45 Neutral	$3.19B	―	-32.02%	―	―	-0.12%
IMVT	38 Underperform	$3.33B	―	-74.17%	―	―	-43.10%

Crinetics Pharmaceuticals Corporate Events

Crinetics Pharmaceuticals Appoints New Chief Financial Officer

On February 24, 2025, Crinetics Pharmaceuticals announced the appointment of Tobin Schilke as Chief Financial Officer, effective February 28, 2025. Mr. Schilke brings over 25 years of global pharmaceutical experience, having previously transformed biotech companies into commercial organizations. His appointment is seen as pivotal as Crinetics prepares for its first commercial launch and advances its development pipeline. The move is expected to accelerate Crinetics’ growth objectives and create long-term value for stakeholders.

Crinetics Pharmaceuticals Outlines 2025 Strategic Priorities

At the J.P. Morgan Healthcare Conference in January 2025, Crinetics Pharmaceuticals outlined its 2025 priorities, including increasing commercial readiness for the potential U.S. launch of paltusotine, pending FDA approval, and advancing clinical development of atumelnant. These efforts reflect Crinetics’ strategic focus on endocrine conditions, aiming to position the company as a leader in this niche market by enhancing patient access to innovative treatments.

Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2

Crinetics Pharmaceuticals announced positive topline results from its Phase 2 study of atumelnant, an ACTH receptor antagonist candidate for treating congenital adrenal hyperplasia (CAH). The study showed significant reductions in key biomarkers and improvements in clinical signs, supporting the initiation of a Phase 3 trial. With atumelnant being well-tolerated and showing no severe adverse events, Crinetics aims to advance its development, furthering its strategy to become a leading global endocrine company.

Crinetics Pharmaceuticals Strengthens Leadership with New Appointment

Crinetics Pharmaceuticals has appointed Isabel Kalofonos as the Chief Commercial Officer to lead the commercial strategy for launching paltusotine, an innovative treatment for acromegaly. With over 20 years of experience in the pharmaceutical and biotech industry, Kalofonos’s appointment suggests a strategic move by Crinetics to strengthen its market position and enhance its pipeline commercialization efforts, potentially impacting stakeholders by advancing new treatments in the endocrine disorders sector.